Therapeutic target database 2026: facilitating targeted therapies and precision medicine

Nucleic Acids Res. 2026 Jan 6;54(D1):D1692-D1701. doi: 10.1093/nar/gkaf1154.

ABSTRACT

Development of targeted therapeutics begins with the discovery and validation of therapeutic targets, which builds the foundation for rational drug design. Extensive information on target-disease associations, target perturbation profiles, drug bioactivity landscapes, and clinical profiles is critical for identifying disease-relevant targets, elucidating their biological functions, and assessing the therapeutic potential. Therapeutic target database 2026 represents a major update that expands multiple layers of data essential for drug discovery. Key expansions include (i) 306 247 target-disease associations covering 2912 targets, (ii) 10 506 perturbation profiles triggered by genetic modification or chemical interference on 2368 targets, (iii) multidimensional activity landscapes of 17 806 drugs, encompassing cytotoxic, antimicrobial-, and molecular-level activities, and (iv) abundant clinical profiles for 2234 approved drugs. As a result, this update provides expanded and curated information on 3798 targets and 40 398 drugs. To enhance usability and scalability, the database framework has been rebuilt, which can be freely accessible without any login requirement at https://idrblab.org/ttd/.

PMID:41243978 | PMC:PMC12807707 | DOI:10.1093/nar/gkaf1154